FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19029957.
- Also identified by DOI 10.1038/nrc2524.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic. After numerous patients with cancer or age-related macular degeneration have been treated with these drugs, they have now become part of the standard range of therapeutic tools. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity. Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment.
Medical subject headings
- Angiogenesis Inhibitors
- Neoplasms
- Vascular Endothelial Growth Factor B
- Vascular Endothelial Growth Factor Receptor-1